Japanese drugmaker Eisai announced Thursday that it has agreed to transfer ownership of its 124-acre campus in Research Triangle Park to Biogen.
Biogen has been leasing space in the facility since 2013. Under the transfer agreement, Biogen will continue to manufacture solid-dose products for Eisai in RTP, as well as Eisai’s parenteral products.
Financial terms of the agreement weren’t disclosed.
The deal expands Biogen’s already large presence in the Triangle, where it now employs 1,300 people at its 158-acre campus in Morrisville.
“This acquisition is one of the successful outcomes of having such a strong life sciences cluster in the Triangle,” Joydeep Ganguly, vice president and general manager of Biogen’s RTP operations, said in a statement.
The property transfer includes all 275,000 square feet of building space on Eisai’s RTP campus in Durham County.
Eisai employs about 180 people at the campus. About 35 of those employees will be laid off as a result of the transfer, said company spokeswoman Suzanne Grogan.
About 100 Eisai employees will be offered jobs with Biogen when the deal closes; the rest will remain with Eisai.
Eisai plans to keep staff of about 45 people in North Carolina to manage its supply chain. The staff will remain on the RTP campus for a six-month transition period until new local office space is found. Eisai also plans to continue manufacturing drugs at its plant in Baltimore, Md.
Cambridge, Mass.-based Biogen now makes its Multiple Sclerosis drug Tecfidera at Eisai’s RTP campus. The Food and Drug Administration approved the site to manufacture the drug in June.
Tecfidera accounted for $825 million in revenue in the first quarter, including $648 million in U.S. sales.
Biogen’s 740,000-square-foot Morrisville campus includes manufacturing and support, such as quality control, engineering and information technology, and also product development for clinical trials, as well as a patient services call center.